drugset / Trial / NCT01199289

A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled Asthma

NCT01199289

Phase 2 Completed 315 enrolled Amgen
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine if AMG 827 is effective compared to placebo as measured by change in Asthma Control Questionnaire (ACQ) composite scores.

Timeline

Start
2010-10-04
Primary completion
2011-12-21
Completion
2011-12-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Brodalumab Monoclonal antibody 140 mg Subcutaneous
Subject Brodalumab Monoclonal antibody 210 mg Subcutaneous
Subject Brodalumab Monoclonal antibody 280 mg Subcutaneous

Indications